Medtronic ((MDT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medtronic recently completed a clinical study titled ‘Product Surveillance Registry (PSR) – Nerve Integrity Monitoring (NIM) Vital Cohort.’ The study aimed to confirm the clinical safety and performance of Medtronic’s NIM Vital™ System and its accessories in real-world surgical settings. This research is significant as it supports the efficacy of the NIM Vital™ System in various surgeries, including intracranial, extracranial, and neck surgeries.
The intervention tested in this study was the Intraoperative Nerve Monitoring device. This device is used for locating, stimulating, and monitoring target nerves during surgical procedures, ensuring the safety and effectiveness of nerve monitoring as part of standard clinical care.
This observational study followed a cohort model, focusing on real-world data collection without any specific allocation or masking. The primary purpose was to gather evidence on the system’s performance in a practical setting, with a target duration of one day per observation.
The study began on September 23, 2024, and reached its primary completion on the same day, reflecting its observational nature. The last update was submitted on September 23, 2025, marking the study’s completion and data analysis phase.
The completion of this study could positively impact Medtronic’s stock performance by reinforcing investor confidence in the company’s product offerings. As the NIM Vital™ System is confirmed to be safe and effective, Medtronic may strengthen its position in the surgical device market, potentially affecting competitor dynamics.
The study is now completed, with further details available on the ClinicalTrials portal.